Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
BTZ-043 Dose Evaluation in Combination and Selection
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 90
- Registration Number
- NCT05926466
- Locations
- 🇹🇿
National Institute for Medical Research (NIMR-Mwanza),, Mwanza, Tanzania
🇿🇦TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa
🇹🇿National Institute for Medical Research (NIMR-MMRC), Mbeya, Tanzania
A TQTc Study for Omaveloxolone
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT05927649
- Locations
- 🇺🇸
Celerion, Inc., Tempe, Arizona, United States
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 44
- Registration Number
- NCT05924815
- Locations
- 🇺🇸
Celerion, Inc 2420, Tempe, Arizona, United States
Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05905484
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Quebec, Canada
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 107
- Registration Number
- NCT05893862
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0003), Glendale, California, United States
🇺🇸Hassman Research Institute Marlton Site ( Site 0001), Marlton, New Jersey, United States
🇺🇸NRC Research Institute ( Site 0004), Orange, California, United States
A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT05878522
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 56
- Registration Number
- NCT05867147
- Locations
- 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States
Thorough QT/QTc Study to Evaluate the Effects of Ecopipam (EBS-101) on Cardiac Repolarization
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05841160
- Locations
- 🇺🇸
PPD Austin Phase 1 Clinical Research Unit, Austin, Texas, United States
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 72
- Registration Number
- NCT05818852
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
🇺🇸ICON Salt Lake City, Salt Lake City, Utah, United States
PanACEA - STEP2C -01
- Conditions
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 270
- Registration Number
- NCT05807399
- Locations
- 🇲🇼
Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi
🇹🇿Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania
🇺🇬Makerere University Lung Institute Limited, Kampala, Uganda
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.